455 related articles for article (PubMed ID: 33472171)
1. Functional characterization of DLK1/MEG3 locus on chromosome 14q32.2 reveals the differentiation of pituitary neuroendocrine tumors.
Chen Y; Gao H; Liu Q; Xie W; Li B; Cheng S; Guo J; Fang Q; Zhu H; Wang Z; Wang J; Li C; Zhang Y
Aging (Albany NY); 2020 Dec; 13(1):1422-1439. PubMed ID: 33472171
[TBL] [Abstract][Full Text] [Related]
2. Silencing of the imprinted DLK1-MEG3 locus in human clinically nonfunctioning pituitary adenomas.
Cheunsuchon P; Zhou Y; Zhang X; Lee H; Chen W; Nakayama Y; Rice KA; Tessa Hedley-Whyte E; Swearingen B; Klibanski A
Am J Pathol; 2011 Oct; 179(4):2120-30. PubMed ID: 21871428
[TBL] [Abstract][Full Text] [Related]
3. Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas.
Gejman R; Batista DL; Zhong Y; Zhou Y; Zhang X; Swearingen B; Stratakis CA; Hedley-Whyte ET; Klibanski A
J Clin Endocrinol Metab; 2008 Oct; 93(10):4119-25. PubMed ID: 18628527
[TBL] [Abstract][Full Text] [Related]
4. Molecular Biology of Pituitary Adenomas.
Faltermeier CM; Magill ST; Blevins LS; Aghi MK
Neurosurg Clin N Am; 2019 Oct; 30(4):391-400. PubMed ID: 31471046
[TBL] [Abstract][Full Text] [Related]
5. Chromosomal instability in the prediction of pituitary neuroendocrine tumors prognosis.
Lasolle H; Elsensohn MH; Wierinckx A; Alix E; Bonnefille C; Vasiljevic A; Cortet C; Decoudier B; Sturm N; Gaillard S; Ferrière A; Roy P; Jouanneau E; Bertolino P; Bardel C; Sanlaville D; Raverot G
Acta Neuropathol Commun; 2020 Nov; 8(1):190. PubMed ID: 33168091
[TBL] [Abstract][Full Text] [Related]
6. Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype.
Chen Y; Gao H; Xie W; Guo J; Fang Q; Zhao P; Liu C; Zhu H; Wang Z; Wang J; Gui S; Zhang Y; Li C
Aging (Albany NY); 2020 Dec; 13(1):1276-1293. PubMed ID: 33472173
[TBL] [Abstract][Full Text] [Related]
7. Lysine Methyltransferase 5A Promotes the Progression of Growth Hormone Pituitary Neuroendocrine Tumors through the Wnt/β-Catenin Signaling Pathway.
Li J; Song H; Chen T; Zhang S; Zhang C; Ma C; Zhang L; Wang T; Qian Y; Deng X
Neuroendocrinology; 2024; 114(6):589-601. PubMed ID: 38565081
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the Paternally-Imprinted DLK1-MEG3 and IGF2-H19 Tandem Gene Loci in NT2 Embryonal Carcinoma Cells Identifies DLK1 as a Potential Therapeutic Target.
Sellers ZP; Schneider G; Maj M; Ratajczak MZ
Stem Cell Rev Rep; 2018 Dec; 14(6):823-836. PubMed ID: 29980981
[TBL] [Abstract][Full Text] [Related]
9. METTL3-mediated RNA m6A Hypermethylation Promotes Tumorigenesis and GH Secretion of Pituitary Somatotroph Adenomas.
Chang M; Wang Z; Gao J; Yang C; Feng M; Niu Y; Tong WM; Bao X; Wang R
J Clin Endocrinol Metab; 2022 Jan; 107(1):136-149. PubMed ID: 34491359
[TBL] [Abstract][Full Text] [Related]
10. Lineage-dependent role of miR-410-3p as oncomiR in gonadotroph and corticotroph pituitary adenomas or tumor suppressor miR in somatotroph adenomas via MAPK, PTEN/AKT, and STAT3 signaling pathways.
Grzywa TM; Klicka K; Rak B; Mehlich D; Garbicz F; Zieliński G; Maksymowicz M; Sajjad E; Włodarski PK
Endocrine; 2019 Sep; 65(3):646-655. PubMed ID: 31165412
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of survivin splice variants in pituitary tumors.
Waligórska-Stachura J; Andrusiewicz M; Sawicka-Gutaj N; Kubiczak M; Jankowska A; Liebert W; Czarnywojtek A; Waśko R; Blanco-Gangoo AR; Ruchała M
Pituitary; 2015 Jun; 18(3):410-6. PubMed ID: 25107550
[TBL] [Abstract][Full Text] [Related]
12.
Tang C; Zhong C; Zhu J; Yuan F; Yang J; Xu Y; Ma C
Oncol Res; 2024; 32(6):1079-1091. PubMed ID: 38827318
[TBL] [Abstract][Full Text] [Related]
13. Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumors.
Yamato A; Nagano H; Gao Y; Matsuda T; Hashimoto N; Nakayama A; Yamagata K; Yokoyama M; Gong Y; Shi X; Zhahara SN; Kono T; Taki Y; Furuki N; Nishimura M; Horiguchi K; Iwadate Y; Fukuyo M; Rahmutulla B; Kaneda A; Hasegawa Y; Kawashima Y; Ohara O; Ishikawa T; Kawakami E; Nakamura Y; Inoshita N; Yamada S; Fukuhara N; Nishioka H; Tanaka T
Commun Biol; 2022 Nov; 5(1):1304. PubMed ID: 36435867
[TBL] [Abstract][Full Text] [Related]
14. Hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) and guanylate kinase 1 (GUK1) are differentially expressed in GH-secreting adenomas.
da Rocha AA; Giorgi RR; de Sa SV; Correa-Giannella ML; Fortes MA; Cavaleiro AM; Machado MC; Cescato VA; Bronstein MD; Giannella-Neto D
Pituitary; 2006; 9(2):83-92. PubMed ID: 16832584
[TBL] [Abstract][Full Text] [Related]
15. Increased methylation upstream of the MEG3 promotor is observed in acute myeloid leukemia patients with better overall survival.
Sellers ZP; Bolkun L; Kloczko J; Wojtaszewska ML; Lewandowski K; Moniuszko M; Ratajczak MZ; Schneider G
Clin Epigenetics; 2019 Mar; 11(1):50. PubMed ID: 30876483
[TBL] [Abstract][Full Text] [Related]
16. DNA Methylation Pattern in Somatotroph Pituitary Neuroendocrine Tumors.
Kober P; Rymuza J; Baluszek S; Maksymowicz M; Nyc A; Mossakowska BJ; Zieliński G; Kunicki J; Bujko M
Neuroendocrinology; 2024; 114(1):51-63. PubMed ID: 37699356
[TBL] [Abstract][Full Text] [Related]
17. Characterization of c-kit (CD117) expression in human normal pituitary cells and pituitary adenomas.
La Rosa S; Uccella S; Dainese L; Marchet S; Placidi C; Vigetti D; Capella C
Endocr Pathol; 2008; 19(2):104-11. PubMed ID: 18568298
[TBL] [Abstract][Full Text] [Related]
18. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
19. Histopathology of growth hormone-secreting pituitary tumors: State of the art and new perspectives.
Guaraldi F; Ambrosi F; Ricci C; Di Sciascio L; Asioli S
Best Pract Res Clin Endocrinol Metab; 2024 May; 38(3):101894. PubMed ID: 38614953
[TBL] [Abstract][Full Text] [Related]
20. Somatotropinomas, but not nonfunctioning pituitary adenomas, maintain a functional apoptotic RET/Pit1/ARF/p53 pathway that is blocked by excess GDNF.
Diaz-Rodriguez E; Garcia-Rendueles AR; Ibáñez-Costa A; Gutierrez-Pascual E; Garcia-Lavandeira M; Leal A; Japon MA; Soto A; Venegas E; Tinahones FJ; Garcia-Arnes JA; Benito P; Angeles Galvez M; Jimenez-Reina L; Bernabeu I; Dieguez C; Luque RM; Castaño JP; Alvarez CV
Endocrinology; 2014 Nov; 155(11):4329-40. PubMed ID: 25137025
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
